Effectiveness of most common first-line empirical treatments per region
| N | Non-evaluable | Failure | Success | Eradication rate | ||||
| n | % | n | n | ITT | PP | mITT | ||
| East | ||||||||
| PPI-C+A | 1775 | 26 | 1.5% | 739 | 1010 | 57.7% | 82.3% | 81.5% |
| PPI-C+M | 28 | 0 | 0.0% | 11 | 17 | 60.7% | 68.0% | 68.0% |
| PPI-A+M | 56 | 0 | 0.0% | 22 | 34 | 60.7% | 75.6% | 75.6% |
| PPI-A+L | 227 | 0 | 0.0% | 191 | 36 | 15.9% | 17.1% | 16.7% |
| PPI-C+A+T seq | 9 | 0 | 0.0% | 9 | 0 | 0.0% | ||
| PPI-C+A+M seq | 25 | 0 | 0.0% | 10 | 15 | 60.0% | 68.2% | 68.2% |
| PPI-C+A+T conc | 1 | 0 | 0.0% | 1 | 0 | 0.0% | ||
| PPI-C+A+M conc | 14 | 0 | 0.0% | 5 | 9 | 64.3% | 90.0% | 90.0% |
| PPI-C+A+B | 800 | 3 | 0.4% | 191 | 606 | 76.0% | 89.6% | 89.2% |
| PPI-M+Tc+B | 30 | 0 | 0.0% | 6 | 24 | 80.0% | 92.3% | 92.3% |
| PPI-M+D+B | 0 | 0 | ||||||
| PPI+single capsule* | 0 | 0 | ||||||
| Other | 714 | 6 | 0.8% | 281 | 427 | 60.3% | 72.6% | 71.9% |
| Total in the region | 3679 | 1466 | 2178 | 59.8% | 77.0% | 76.3% | ||
| South-east | ||||||||
| PPI-C+A | 2571 | 113 | 4.4% | 1013 | 1445 | 58.8% | 86.7% | 86.6% |
| PPI-C+M | 816 | 7 | 0.9% | 217 | 592 | 73.2% | 85.4% | 85.3% |
| PPI-A+M | 92 | 0 | 0.0% | 64 | 28 | 30.4% | 80.0% | 80.0% |
| PPI-A+L | 28 | 0 | 0.0% | 6 | 22 | 78.6% | 84.0% | 84.6% |
| PPI-C+A+T seq | 68 | 0 | 0.0% | 9 | 59 | 86.8% | 86.8% | 86.8% |
| PPI-C+A+M seq | 175 | 0 | 0.0% | 37 | 138 | 78.9% | 84.7% | 81.2% |
| PPI-C+A+T conc | 51 | 0 | 0.0% | 4 | 47 | 92.2% | 94.0% | 92.2% |
| PPI-C+A+M conc | 250 | 0 | 0.0% | 28 | 222 | 88.8% | 91.7% | 91.4% |
| PPI-C+A+B | 0 | 0 | ||||||
| PPI-M+Tc+B | 7 | 0 | 0.0% | 1 | 6 | 85.7% | 100.0% | 100.0% |
| PPI-M+D+B | 2 | 0 | 0.0% | 1 | 1 | 50.0% | 50.0% | 50.0% |
| PPI+single capsule* | 1 | 0 | 0.0% | 0 | 1 | 100.0% | 100.0% | 100.0% |
| Other | 238 | 9 | 3.8% | 73 | 156 | 68.1% | 83.3% | 83.0% |
| Total in the region | 4299 | 1453 | 2717 | 65.2% | 86.5% | 86.2% | ||
| South-west | ||||||||
| PPI-C+A | 3160 | 1 | 0.0% | 682 | 2477 | 78.4% | 84.3% | 83.7% |
| PPI-C+M | 127 | 0 | 0.0% | 55 | 72 | 56.7% | 63.7% | 63.2% |
| PPI-A+M | 51 | 0 | 0.0% | 13 | 38 | 74.5% | 79.2% | 77.6% |
| PPI-A+L | 132 | 1 | 0.8% | 24 | 107 | 81.7% | 85.2% | 84.9% |
| PPI-C+A+T seq | 4 | 0 | 0.0% | 1 | 3 | 75.0% | 100.0% | 100.0% |
| PPI-C+A+M seq | 281 | 0 | 0.0% | 65 | 216 | 76.9% | 84.2% | 81.8% |
| PPI-C+A+T conc | 0 | 0 | ||||||
| PPI-C+A+M conc | 3910 | 12 | 0.3% | 540 | 3358 | 86.1% | 90.3% | 89.8% |
| PPI-C+A+B | 956 | 10 | 1.0% | 108 | 838 | 88.6% | 91.7% | 91.6% |
| PPI-M+Tc+B | 41 | 0 | 0.0% | 8 | 33 | 80.5% | 84.6% | 82.5% |
| PPI-M+D+B | 56 | 0 | 0.0% | 11 | 45 | 80.4% | 82.4% | 81.8% |
| PPI+single capsule* | 1144 | 43 | 3.8% | 151 | 950 | 86.3% | 95.2% | 94.6% |
| Other | 256 | 5 | 2.0% | 82 | 169 | 67.3% | 78.3% | 76.8% |
| Total in the region | 10 118 | 1740 | 8306 | 82.7% | 88.1% | 87.5% | ||
| Centre | ||||||||
| PPI-C+A | 132 | 0 | 0.0% | 56 | 76 | 57.6% | 85.7% | 85.4% |
| PPI-C+M | 4 | 0 | 0.0% | 1 | 3 | 75.0% | 100.0% | 75.0% |
| PPI-A+M | 3 | 0 | 0.0% | 0 | 3 | 100.0% | 100.0% | 100.0% |
| PPI-A+L | 6 | 0 | 0.0% | 3 | 3 | 50.0% | 75.0% | 60.0% |
| PPI-C+A+T seq | 1128 | 70 | 6.2% | 243 | 815 | 77.0% | 92.4% | 91.7% |
| PPI-C+A+M seq | 92 | 0 | 0.0% | 35 | 57 | 62.0% | 87.5% | 86.4% |
| PPI-C+A+T conc | 121 | 3 | 2.5% | 14 | 104 | 88.1% | 96.3% | 93.7% |
| PPI-C+A+M conc | 1 | 0 | 0.0% | 1 | 0 | 0.0% | ||
| PPI-C+A+B | 0 | 0 | ||||||
| PPI-M+Tc+B | 99 | 0 | 0.0% | 28 | 71 | 71.7% | 95.9% | 95.9% |
| PPI-M+D+B | 0 | 0 | ||||||
| PPI+single capsule* | 189 | 8 | 4.2% | 82 | 99 | 54.7% | 98.0% | 95.2% |
| Other | 210 | 2 | 1.0% | 164 | 44 | 21.2% | 84.6% | 83.0% |
| Total in the region | 1985 | 627 | 1275 | 67.0% | 92.3% | 91.2% | ||
| North | ||||||||
| PPI-C+A | 840 | 1 | 0.1% | 178 | 661 | 78.8% | 84.8% | 84.3% |
| PPI-C+M | 71 | 0 | 0.0% | 21 | 50 | 70.4% | 76.6% | 75.8% |
| PPI-A+M | 359 | 0 | 0.0% | 72 | 287 | 79.9% | 86.5% | 86.7% |
| PPI-A+L | 12 | 0 | 0.0% | 3 | 9 | 75.0% | 90.0% | 90.0% |
| PPI-C+A+T seq | 19 | 0 | 0.0% | 10 | 9 | 47.4% | 100.0% | 100.0% |
| PPI-C+A+M seq | 47 | 0 | 0.0% | 13 | 34 | 72.3% | 71.1% | 72.3% |
| PPI-C+A+T conc | 17 | 0 | 0.0% | 12 | 5 | 29.4% | 100.0% | 100.0% |
| PPI-C+A+M conc | 1 | 0 | 0.0% | 1 | 0 | 0.0% | ||
| PPI-C+A+B | 0 | 0 | ||||||
| PPI-M+Tc+B | 15 | 0 | 0.0% | 3 | 12 | 80.0% | 91.7% | 92.3% |
| PPI-M+D+B | 1 | 0 | 0.0% | 0 | 1 | 100.0% | 100.0% | 100.0% |
| PPI+single capsule* | 17 | 0 | 0.0% | 4 | 13 | 76.5% | 92.9% | 86.7% |
| Other | 53 | 0 | 0.0% | 20 | 33 | 62.3% | 84.2% | 84.6% |
| Total in the region | 1452 | 337 | 1114 | 76.8% | 84.7% | 84.4% | ||
| All regions | ||||||||
| PPI-C+A | 8478 | 141 | 1.7% | 2668 | 5669 | 68.0% | 84.6% | 84.1% |
| PPI-C+M | 1046 | 7 | 0.7% | 305 | 734 | 70.6% | 81.6% | 81.3% |
| PPI-A+M | 561 | 0 | 0.0% | 171 | 390 | 69.5% | 84.3% | 84.2% |
| PPI-A+L | 405 | 1 | 0.2% | 227 | 177 | 43.8% | 46.6% | 46.3% |
| PPI-C+A+T seq | 1228 | 70 | 5.7% | 272 | 886 | 76.5% | 92.1% | 91.4% |
| PPI-C+A+M seq | 620 | 0 | 0.0% | 160 | 460 | 74.2% | 83.0% | 80.8% |
| PPI-C+A+T conc | 190 | 3 | 1.6% | 31 | 156 | 83.4% | 95.7% | 93.4% |
| PPI-C+A+M conc | 4176 | 12 | 0.3% | 575 | 3589 | 86.2% | 90.4% | 89.9% |
| PPI-C+A+B | 1756 | 13 | 0.7% | 299 | 1444 | 82.8% | 90.8% | 90.6% |
| PPI-M+Tc+B | 192 | 0 | 0.0% | 46 | 146 | 76.0% | 92.4% | 91.8% |
| PPI-M+D+B | 59 | 0 | 0.0% | 12 | 47 | 79.7% | 81.5% | 81.0% |
| PPI+single capsule* | 1351 | 51 | 3.8% | 237 | 1063 | 81.8% | 95.5% | 94.6% |
| Other | 1471 | 22 | 1.5% | 620 | 829 | 57.2% | 76.6% | 75.8% |
| Total in all regions | 21 533 | 320 | 1.5% | 5623 | 15 590 | 73.5% | 86.2% | 85.6% |
*Three-in-one single capsule containing bismuth, tetracycline and metronidazole.
A, amoxicillin; B, bismuth salts; C, clarithromycin; Conc, concomitant; D, doxycycline; L, levofloxacin; M, metronidazole; mITT, modified intention-to-treat; PP, per protocol; PPI, proton pump inhibitor; Seq, sequential; Tc, tetracycline.